COMBINED THERAPY BY LASMIDITAN AND CGRP ANTAGONIST FOR APPLICATION IN THE TREATMENT OF MIGRAINE

摘要

This invention relates to combinations of lasmiditan and a calcitonin gene-related peptide antagonist (CGRP - Calcitonin gene-related peptide), for example, to a combination of lasmiditan and galcanesumab, and to methods of using these combinations for the treatment of migraine, in particular migraine, not sufficiently controlled by lasmiditan therapy or a CGRP antagonist in monotherapy, and more specifically for the treatment of treatment-resistant migraine, which is defined herein as a migraine resistant to the previous two or more treatment regimens as monotherapy and / or dual therapy.